Introduction：Basic information about CAS 742112-33-0|OSU-03012 (AR-12), including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | OSU-03012 (AR-12) |
|---|
| CAS Number | 742112-33-0 | Molecular Weight | 460.451 |
|---|
| Density | 1.4±0.1 g/cm3 | Boiling Point | 683.0±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C26H19F3N4O | Melting Point | 177-180 °C |
|---|
| MSDS | / | Flash Point | 366.9±31.5 °C |
|---|
Names
| Name | 2-amino-N-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide |
|---|
| Synonym | More Synonyms |
|---|
OSU-03012 (AR-12) BiologicalActivity
| Description | OSU-03012 is a PDK-1 inhibitor with an IC50 of 5 μM. |
|---|
| Related Catalog | Signaling Pathways >>PI3K/Akt/mTOR >>PDK-1Research Areas >>Cancer |
|---|
| Target | IC50: 5 μM (PDK-1)[1] |
|---|
| In Vitro | OSU-03012 inhibits PC-3 cells viability with IC50 values of 5 μM. The effects of OSU-03012 on PC-3 cell proliferation in 10% FBS-supplemented medium are also examined. OSU-03012 induces apoptotic death in PC-3 cells in 1% FBS-containing medium in a dose-dependent manner, as demonstrated by DNA fragmentation and PARP cleavage. OSU-03012 is effective in suppressing PC-3 cell proliferation at sub-μM, consistent with that noted in 1% serum[1]. |
|---|
| In Vivo | All of the SCID/Rag2 mice develop two MDA-MB-435/LCC6/Her-2 tumors and are assigned to either the vehicle control or OSU-03012 (200 mg/kg) treatment group, which is given orally for 3 days. OSU-03012 remarkably decreases EGFR protein expression in the tumors by ~48% compared with expression levels found in the tumors taken from mice that receive the vehicle control. OSU-03012 also prevents Y-box binding protein-1 (YB-1) from binding to the EGFR promoter at the 1b and 2a sites[2]. |
|---|
| Cell Assay | PC-3 (p53-/-) human androgen-nonresponsive prostate cancer cells are cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified incubator containing 5% CO2. The effect of Celecoxib and its derivatives (e.g., OSU-03012) (2.5 μM, 5 μM, 7.5 μM and 10 μM) on PC-3 cell viability is assessed by using the MTT assay in six replicates. Cells are grown in 10% FBS- supplemented RPMI 1640 in 96-well, flat-bottomed plates for 24 h, and are exposed to various concentrations of Celecoxib derivatives (e.g., OSU-03012) dissolved in DMSO (final concentration ≤0.1%) in 1% serum-containing RPMI 1640 for different time intervals. Controls receive DMSO vehicle at a concentration equal to that in drug-treated cells. The medium is removed, replaced by 200 μL of 0.5 mg/mL of MTT in 10% FBS-containing RPMI 1640, and cells are incubated in the CO2 incubator at 37°C for 2 h. Supernatants are removed from the wells, and the reduced MTT dye is solubilized in 200 μL/well DMSO. Absorbance at 570 nm is determined on a plate reader[1]. |
|---|
| Animal Admin | Mice[2] SCID/Rag2m mice (6-8 weeks old, female) are subcutaneously injected with 1×107 MDA-MB-435/LCC6 cells stably transfected with HER-2/neu. Each mouse is inoculated with the cells on the right and left sides of the lower back. A total of eight mice are injected, each harboring two tumors. After 6 weeks, the mice are randomly assigned into groups (vehicle, 0.5% methyl cellulose/0.1% Tween 80, or OSU-03012 at 200 mg/kg/day). Mice are dosed daily for 3 days with either the vehicle or OSU-03012 by oral gavage. On the fourth day, the study is terminated, mice are sacrificed, and the tumors are collected for chromatin immunoprecipitation (ChIP) and protein isolations. |
|---|
| References | [1]. Zhu J, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004 Jun 15;64(12):4309-18. [2]. To K, et al. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor. Mol Pharmacol. 2007 Sep;72(3):641-52. |
|---|
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|
| Boiling Point | 683.0±55.0 °C at 760 mmHg |
|---|
| Melting Point | 177-180 °C |
|---|
| Molecular Formula | C26H19F3N4O |
|---|
| Molecular Weight | 460.451 |
|---|
| Flash Point | 366.9±31.5 °C |
|---|
| Exact Mass | 460.151093 |
|---|
| PSA | 72.94000 |
|---|
| LogP | 5.38 |
|---|
| Vapour Pressure | 0.0±2.1 mmHg at 25°C |
|---|
| Index of Refraction | 1.649 |
|---|
| InChIKey | YULUCECVQOCQFQ-UHFFFAOYSA-N |
|---|
| SMILES | NCC(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc3c(ccc4ccccc43)c2)cc1 |
|---|
| Storage condition | -20°C |
|---|
Synonyms
| PDK1 inhibitor AR-12 |
| Acetamide, 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- |
| N-{4-[5-(2-Phenanthryl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}glycinamide |
| OSU-03012 |
| S1106_Selleck |
| 2-amino-N-(4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)acetamide |
| OSU03012 |
